Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Innate Pharma nets $73.5mm in initial public offering

Executive Summary

Innate Pharma SA (therapeutics antibodies for cancer) netted $73.5mm through its initial public offering on the Nasdaq Global Select Market. (The company debuted on Euronext Paris in 2006.) Of the 14.4mm ordinary shares issued (including the overallotment), 9.22mm were in the form of American Depositary Shares and were sold at $5.50 while 4.45mm were ordinary shares sold to European and other ex-US investors at €4.97. The company originally filed to sell 10.67mm shares.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies